ES2496965T3 - Uso de Lactobacillus kefiranofaciens como un probiótico y un simbiótico - Google Patents

Uso de Lactobacillus kefiranofaciens como un probiótico y un simbiótico Download PDF

Info

Publication number
ES2496965T3
ES2496965T3 ES06705161.5T ES06705161T ES2496965T3 ES 2496965 T3 ES2496965 T3 ES 2496965T3 ES 06705161 T ES06705161 T ES 06705161T ES 2496965 T3 ES2496965 T3 ES 2496965T3
Authority
ES
Spain
Prior art keywords
methyl
lactobacillus kefiranofaciens
probiotic
gluconate
symbiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06705161.5T
Other languages
English (en)
Spanish (es)
Inventor
Pierre Lemieux
Louis-Philippe Precourt
Eric Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOLACTIS Inc
Original Assignee
BIOLACTIS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOLACTIS Inc filed Critical BIOLACTIS Inc
Application granted granted Critical
Publication of ES2496965T3 publication Critical patent/ES2496965T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
    • A23C21/026—Whey; Whey preparations containing, or treated with, microorganisms or enzymes containing, or treated only with, lactic acid producing bacteria, bifidobacteria or propionic acid bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ES06705161.5T 2005-02-11 2006-02-10 Uso de Lactobacillus kefiranofaciens como un probiótico y un simbiótico Expired - Lifetime ES2496965T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65165705P 2005-02-11 2005-02-11
US651657P 2005-02-11
PCT/CA2006/000206 WO2006084381A1 (en) 2005-02-11 2006-02-10 Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic

Publications (1)

Publication Number Publication Date
ES2496965T3 true ES2496965T3 (es) 2014-09-22

Family

ID=36792883

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06705161.5T Expired - Lifetime ES2496965T3 (es) 2005-02-11 2006-02-10 Uso de Lactobacillus kefiranofaciens como un probiótico y un simbiótico

Country Status (8)

Country Link
US (2) US20090130072A1 (https=)
EP (1) EP1853284B1 (https=)
JP (2) JP5401733B2 (https=)
CA (1) CA2597229A1 (https=)
DK (1) DK1853284T3 (https=)
ES (1) ES2496965T3 (https=)
MX (1) MX2007009659A (https=)
WO (1) WO2006084381A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤
US20110002994A1 (en) * 2007-10-02 2011-01-06 Institut National De La Recherche Scientifique Method of regulating the th17 pathway and its associated metabolic impact
JP2010037225A (ja) * 2008-08-01 2010-02-18 Nippon Kefia Kk 乳清ケフィアを有効成分として含んでなる体脂肪減少剤
JP2012034616A (ja) * 2010-08-06 2012-02-23 Umeya Co Ltd 塩たらこの製造方法及び塩たらこ、並びに辛子明太子の製造方法及び辛子明太子
JP5840368B2 (ja) 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
KR101779719B1 (ko) 2016-08-30 2017-09-19 건국대학교 산학협력단 신규한 락토바실러스 케피아노파시엔스 dn1 균주 및 이를 포함하는 변비의 예방 또는 치료용 조성물
CN106937745A (zh) * 2016-08-31 2017-07-11 快醒生物科技（北京）有限公司 一种具有改善肠道功能的保健品及其制备方法
JP7482494B2 (ja) * 2016-11-01 2024-05-14 慶應義塾 Ｔｈ１細胞を誘導する細菌
KR102089938B1 (ko) * 2016-12-21 2020-03-17 (주)프로스테믹스 케피어 그레인 유래 미세소포체의 용도
KR101930143B1 (ko) * 2016-12-21 2018-12-17 건국대학교 산학협력단 유산균 유래 세포외다당류를 함유하는 항균 조성물
JP7542798B2 (ja) * 2017-08-10 2024-09-02 株式会社Ｎｒｌファーマ 妊娠中の母子の健康状態改善剤
US10632161B1 (en) 2019-05-23 2020-04-28 Prostemics Co. Ltd. Method for ameliorating or treating a bowel disease
CN111575202A (zh) * 2020-05-19 2020-08-25 北京科拓恒通生物技术股份有限公司 一株用于预防辅助治疗ⅱ型糖尿病的干酪乳杆菌及其应用
CN111808910A (zh) * 2020-07-22 2020-10-23 南京农业大学 一种评价膳食多糖活性的方法
KR20220061555A (ko) * 2020-11-06 2022-05-13 (주)프로스테믹스 신규한 락토바실러스 속 균주 및 상기 균주 유래 세포외 소포의 용도
JP7696856B2 (ja) * 2022-03-31 2025-06-23 よつ葉乳業株式会社 ケフィアグレイン類似物の作出方法並びにケフィアグレイン類似物を用いた発酵乳の製造方法
CN114805474B (zh) * 2022-04-02 2024-03-22 中国海洋大学 一株干酪乳杆菌fn345及其在制备预防辅食期婴儿腹泻菌剂中的应用
CN116948916B (zh) * 2023-08-11 2024-06-11 四川大学 一种干酪乳杆菌及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55113718A (en) * 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
JPH05301812A (ja) * 1992-04-23 1993-11-16 Sansho Seiyaku Co Ltd 皮膚外用剤
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20020182274A1 (en) * 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
JP2002330798A (ja) * 2001-05-11 2002-11-19 Yamato Yakuhin Kk 多糖製造方法
ES2451618T3 (es) * 2001-12-20 2014-03-28 Biolactis Inc. Matriz de proteína maleable y usos de estas

Also Published As

Publication number Publication date
EP1853284A4 (en) 2012-03-21
MX2007009659A (es) 2008-01-16
EP1853284B1 (en) 2014-04-09
WO2006084381A1 (en) 2006-08-17
JP2013139462A (ja) 2013-07-18
US20090130072A1 (en) 2009-05-21
JP5401733B2 (ja) 2014-01-29
DK1853284T3 (da) 2014-07-14
EP1853284A1 (en) 2007-11-14
US20140193383A1 (en) 2014-07-10
JP2008530034A (ja) 2008-08-07
CA2597229A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
ES2496965T3 (es) Uso de Lactobacillus kefiranofaciens como un probiótico y un simbiótico
Collado et al. Potential probiotic characteristics of Lactobacillus and Enterococcus strains isolated from traditional dadih fermented milk against pathogen intestinal colonization
Arboleya et al. Characterization and in vitro properties of potentially probiotic Bifidobacterium strains isolated from breast-milk
Meidong et al. A novel probiotic Bacillus siamensis B44v isolated from Thai pickled vegetables (Phak-dong) for potential use as a feed supplement in aquaculture
Davoodabadi et al. Antibacterial activity of Lactobacillus spp. isolated from the feces of healthy infants against enteropathogenic bacteria
Liu et al. News & notes: Isolation of Vibrio harveyi from diseased kuruma prawns Penaeus japonicus
Guerra-Ordaz et al. Lactulose and Lactobacillus plantarum, a potential complementary synbiotic to control postweaning colibacillosis in piglets
Lagier et al. Current and past strategies for bacterial culture in clinical microbiology
Kim et al. Inhibition of Escherichia coli O157: H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells
Kim et al. Probiotic properties of Lactobacillus and Bifidobacterium strains isolated from porcine gastrointestinal tract
Evans et al. First isolation and characterization of Lactococcus garvieae from Brazilian Nile tilapia, Oreochromis niloticus (L.), and pintado, Pseudoplathystoma corruscans (Spix & Agassiz)
Piotrowski et al. Fructooligosaccharides and mannose affect Clostridium difficile adhesion and biofilm formation in a concentration-dependent manner
Martín-Peláez et al. In vitro fermentation of carbohydrates by porcine faecal inocula and their influence on Salmonella Typhimurium growth in batch culture systems
Ozutsumi et al. Culture-independent analysis of fecal microbiota in cattle
Joseph et al. Isolation and characterization of Vibrio cholerae O139 associated with mass mortality in Penaeus monodon and experimental challenge in postlarvae of three species of shrimp
Shabana et al. Investigation of viral and bacterial enteropathogens of diarrheic sheep and goats in Medina, Saudi Arabia
Pal et al. Isolation, identification and molecular characterization of Vibrio parahaemolyticus from fish samples in Kolkata.
Kumar et al. Association of Enterobacter cloacae in the mortality of Pangasianodon hypophthalmus (Sauvage, 1878) reared in culture pond in Bhimavaram, Andhra Pradesh, India
Mappley et al. Lactobacilli antagonize the growth, motility, and adherence of Brachyspira pilosicoli: a potential intervention against avian intestinal spirochetosis
Torkan et al. Detection of virulence and antibacterial resistance genes in Salmonella isolates from diarrhoeic dogs in Iran
Linh et al. Screening of lactic acid bacteria isolated from fermented food as potential probiotics for aquacultured carp and amberjack
Zhang et al. Isolation and characterization of new probiotic strains from Chinese babies
Cvetnić et al. Mycobacterial infection of pigs in Croatia
Begum et al. Molecular and phenotypic characterization of shigatoxigenic Escherichia coli (STEC) and enteropathogenic E. coli (EPEC) from piglets and infants associated with diarrhoea in Mizoram, India
Ozgun et al. Identification of Lactobacillus strains isolated from faecal specimens of babies and human milk colostrum by API 50 CHL system